In those studies, ocrelizumab was compared with interferon beta-1a for patients with relapsing MS, the most common form of the disease. MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the brain, spinal cord and optic nerves, causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability. https://youtube.com/watch?feature=youtu.be&v=Pf7JuJcVzQUMost people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms, but typically without distinct relapses or periods of remission. Approximately 10-15 percent of people with MS are diagnosed with the primary progressive form of the disease. http://www.pfcdavidlawrence.org/justhenryreyes/2016/07/28/it-wasnt-until-1959-that-the-first-judicial-exception-to-the-at-will-rule-was-created-by-the-california-court-of-appealsThere are no approved treatments for PPMS. Results of the phase 3 trial, which compared ocrelizumab with placebo, showed a reduction in the progression of clinical disability, which was sustained for 12 weeks. The secondary endpoints in all three studies were also met, including multiple measures of disability progression and brain lesion activity. During ORATORIO, 732 patients either received intravenous infusions of OCREVUS or placebo. In contrast to the OPERA I and OPERA II studies, where the blinded treatment period was two years, the blinded treatment period of the ORATORIO study continued beyond that until all patients had received at least 120 weeks of either OCREVUS or placebo and a predefined number of confirmed disability progression events was reached overall in the study.
For the original version including any supplementary images or video, visit https://www.eurekalert.org/pub_releases/2016-12/uoth-uwi122116.php